晚期非小细胞肺癌组织中切除修复交叉互补基因1和核糖核苷酸还原酶亚单位1表达与吉西他滨联合顺铂治疗的相关性研究  

Correlation of expression of RRM1 and ERCC1 and the efficacy of gemcitabine combined with cisplatin chemotherapy in advanced non-small cell lung cancer

作　　者：陈伟文[1] 王志刚[1] 郑锦阳[2] 沈冰寒[1] 郭伟峰[1] 叶晓艺[1] 

机构地区：[1]福建医科大学附属泉州市第一医院呼吸内科 [2]福建医科大学附属泉州市第一医院病理科,泉州362000

出　　处：《中国肿瘤临床与康复》2012年第6期506-508,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨核苷酸切除修复交叉互补基因1(ERCC1)和核糖核苷酸还原酶(RR)亚单位M1(RRM1)在Ⅳ期非小细胞肺癌(NSCLC))组织中的表达水平,分析其与吉西他滨联合顺铂(GP)方案化疗疗效的关系。方法采用液相芯片技术检测148例经过4个周期以上GP方案化疗的Ⅳ期NSCLC组织中RRM1和ERCC1的表达情况。结果Ⅳ期NSCLC组织中ERCC1的阳性率为47.3%,RRM1的阳性率为35.1%,与患者的性别、年龄及是否吸烟无关。ERCC1和RRM1低表达者接受GP方案化疗的效果均优于高表达者,两者差异有统计学意义(P<0.05)。此外,RRM1低表达的患者生存时间明显长于高表达者(P=0.004)。结论晚期NSCLC患者组织中ERCC1和RRM1mRNA的表达与GP方案化疗疗效及预后密切相关。Objective To evaluate the relationship between the expression of ERCC1 and RRM1 and the efficacy of chemotherapy in advanced stage non-small cell lung cancer（NSCLC） patients treated by gemcitabine plus cisplatin chemotherapy（GP）.Methods Liquichip assay was used to investigate the expression of ERCC1 and RRM1 mRNA in 148 patients treated by at least 4 cycles of GP regimen.Results The positive rates of ERCC1 and RRM1 expression in stage Ⅳ NSCLC were 47.3% and 35.1% respectively.There were no correlation with patient gender,age and smoking.The therapeutic effect of GP regimen in patients with ERCC1 and RRM1 low expression was obviously better than that with ERCC1 high expression（P0.05）.overall survival of patients with ERCC1/RRM1 low expression were obviously longer than those with high expression（P=0.004）.Conclusions The expression of ERCC1 and RRM1 mRNA in advanced stage NSCLC patients are closely related to the response to GP regimen and prognosis.

关 键 词：癌 非小细胞肺 切除修复交叉互补基因1 核糖核苷酸还原酶亚单位1 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]